Active Ingredient(s): Lanadelumab (shp643)
FDA Approved: * August 23, 2018
Pharm Company: * DYAX CORP.

Lanadelumab (INN; trade name Takhzyro) is a human monoclonal antibody (class IgG1 kappa)[2] that targets plasma kallikrein (pKal)[3] in order to promote prevention of angioedema in patients with hereditary angioedema.[4][5] Lanadelumab, was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent hereditary angioedema (HAE) attacks.[6][7] Takhzy... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Takhzyro 300 mg/2ml Subcutaneous Injection, Solution
NDC: 47783-644
Dyax Corp.
Takhzyro 150 mg/ml Subcutaneous Solution
NDC: 47783-645
Takeda Pharmaceuticals America, Inc.
Takhzyro 300 mg/2ml Subcutaneous Solution
NDC: 47783-646
Takeda Pharmaceuticals America, Inc.